T 0526/21 (Oral Formulations of Deferasirox / NOVARTIS) of 24.01.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T052621.20230124
- Date of decision
- 24 January 2023
- Case number
- T 0526/21
- Petition for review of
- -
- Application number
- 14710654.6
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- ORAL FORMULATIONS OF DEFERASIROX
- Applicant name
- Novartis AG
- Opponent name
- Teva Pharmaceutical Industries Ltd.
HGF Limited
INVOKAT Intellectual Property Services - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 012(2)Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Keywords
- Item of evidence filed after summons - admitted (yes)
Amendments - allowable (yes)
Inventive step - no reasonable expectation of success
Amendment to case - amendment admitted (no) - Catchword
- -
Order
For these reasons it is decided that:
The appeals are dismissed.